KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Other Working Capital Changes (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Other Working Capital Changes for 6 consecutive years, with $836000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Working Capital Changes fell 97.06% year-over-year to $836000.0, compared with a TTM value of -$32.9 million through Dec 2025, down 642.56%, and an annual FY2025 reading of -$32.9 million, down 642.56% over the prior year.
  • Other Working Capital Changes was $836000.0 for Q4 2025 at Recursion Pharmaceuticals, up from -$3.5 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $126.8 million in Q3 2022 and bottomed at -$27.9 million in Q3 2023.
  • Average Other Working Capital Changes over 5 years is $5.1 million, with a median of -$1.5 million recorded in 2022.
  • Peak annual rise in Other Working Capital Changes hit 2813.12% in 2021, while the deepest fall reached 5600.58% in 2021.
  • Year by year, Other Working Capital Changes stood at $12.9 million in 2021, then plummeted by 206.21% to -$13.7 million in 2022, then soared by 400.67% to $41.1 million in 2023, then tumbled by 30.82% to $28.4 million in 2024, then plummeted by 97.06% to $836000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for RXRX at $836000.0 in Q4 2025, -$3.5 million in Q3 2025, and -$20.5 million in Q2 2025.